Paper Details

  1. Home
  2. Paper Details

Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.

Author: BaldusStephan, DumitrescuDaniel, GerhardtFelix, HellmichMartin, KramerTilmann, OrlovaKristina, RosenkranzStephan, Ten FreyhausHenrik

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article investigates the efficacy and safety of PDE5i in patients with heart failure with preserved ejection fraction (HFpEF) and combined post- and pre-capillary pulmonary hypertension (CpcPH). The study aims to address the uncertainty surrounding the therapeutic consequences of current guidelines for sub-classifying HFpEF patients based on pulmonary vascular resistance and diastolic pressure gradient.
Paper Details　
Original Abstract of the Article :
Heart failure with preserved ejection fraction (HFpEF) is frequently associated with pulmonary hypertension (PH), which substantially impacts survival. Based on pulmonary vascular resistance (PVR) and the diastolic pressure gradient (DPG), current guidelines distinguish between isolated post-capilla...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ijcard.2018.12.078

データ提供：米国国立医学図書館（NLM）

PDE5i: A Potential Treatment for Heart Failure with Preserved Ejection Fraction (HFpEF)?

Heart failure with preserved ejection fraction (HFpEF) is a complex condition characterized by a weakened heart muscle and increased pressure in the pulmonary arteries (pulmonary hypertension or PH). This study investigates the therapeutic potential of phosphodiesterase type 5 inhibitors (PDE5i) in patients with HFpEF and combined post- and pre-capillary PH (CpcPH). The researchers aim to understand if PDE5i can effectively manage the symptoms and improve outcomes for these patients. It's like searching for an oasis of relief in the vast desert of heart failure.

The Promise of PDE5i in HFpEF

PDE5i, a class of drugs commonly used for erectile dysfunction, is being explored as a potential treatment for HFpEF due to its ability to relax blood vessels. This research delves into the efficacy and safety of PDE5i in patients with HFpEF and CpcPH. The findings could provide valuable insights into the potential of this drug to improve the lives of individuals struggling with HFpEF. It's like discovering a hidden spring of hope in the heart of the desert.

HFpEF: A Challenging Condition

HFpEF is a challenging condition to treat, and the lack of effective therapies is a major concern for healthcare professionals. This research is a vital step towards understanding the potential of PDE5i in managing HFpEF. It could lead to new treatment options and offer hope to patients seeking relief from this debilitating condition. It's like a quest for a better future in the face of a challenging desert environment.

Dr.Camel's Conclusion

This research explores the potential of PDE5i, a class of drugs typically used for erectile dysfunction, to treat heart failure with preserved ejection fraction (HFpEF). This is a promising avenue for improving patient outcomes, as HFpEF is a challenging condition to manage. The findings of this study could lead to new treatment options and offer hope to patients seeking relief.

Date :
  1. Date Completed 2019-12-30
  2. Date Revised 2019-12-30
Further Info :

Pubmed ID

30777406

DOI: Digital Object Identifier

10.1016/j.ijcard.2018.12.078

Related Literature

Article Analysis
・Side Effects of tadalafil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.